What is Ruxolitinib cream?

Ruxolitinib cream cream) is a topical Janus kinase (JAK) inhibitor used to treat atopic dermatitis (AD) and non-segmental vitiligo. After approval for marketing, it is suitable for patients aged < topical short-term and discontinuous chronic treatment of mild to moderate atopic dermatitis in non-immune deficient patients 12 years of age and older, and topical treatment of non-segmental vitiligo in adults and children 2 years of age and older.

Ruxolitinib cream is the first and only topical Janus kinase (JAK) inhibitor approved for use in the United States by the U.S. Food and Drug Administration (FDA). Oral formulations of ruxolitinib were first approved in 2011 under the trade name Jakafi for the treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease. Overactivity of the JAK signaling pathway has been shown to contribute to inflammation in atopic dermatitis and vitiligo. Ruxolitinib cream reduces inflammation by inhibiting JAK.

The original drug of ruxolitinib cream has not yet been marketed in China, so it cannot be included in medical insurance. The price of ruxolitinib cream Original drug, specificationsinn 1.5%*60g, which is marketed overseas, is around RMB 20,000 per tube (the price may fluctuate due to the exchange rate), which is relatively expensive. The price of generic ruxolitinib cream marketed overseas is relatively cheap, and its pharmaceutical ingredients are basically the same as those of the original drug. The price of the specificationinn 1.5%*30g produced by a Bangladesh pharmaceutical factory is around 600 yuan per tube (the price may fluctuate due to exchange rate effects).